HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic.
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
11 Dec 2023
11 Dec 2023
Historique:
accepted:
18
10
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
aheadofprint
Résumé
Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) provides a critical intervention toward ending the HIV epidemic and protecting people with reasons to utilize PrEP. PrEP options continue to expand as new administration modalities offer the potential to tailor PrEP use for individual success. We have provided the evidence for new and emerging antiretroviral agents for PrEP (cabotegravir, lenacapavir, dapivirine, and broadly neutralizing antibodies), divided into pharmacology, animal model, and human data, accompanied by a summary and suggested place in therapy. Cabotegravir is a US Food and Drug Administration (FDA)-approved intramuscular injection given every 2 months with a strong body of evidence demonstrating efficacy for HIV PrEP, lenacapavir administered subcutaneously every 6 months is currently under investigation for HIV PrEP, dapivirine vaginal ring is an available PrEP option for women in certain areas of Africa, and broadly neutralizing monoclonal antibodies have been challenged in demonstrating efficacy in phase 1-2 study for HIV PrEP to date. Clinical literature for individual agents is discussed with data from major studies summarized in tables. This review provides a detailed overview of recently available and premier candidate PrEP drugs.
Identifiants
pubmed: 38079092
doi: 10.1007/s40265-023-01963-9
pii: 10.1007/s40265-023-01963-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Ending the HIV Epidemic in the U.S. | HRSA. Available from: https://www.hrsa.gov/ending-hiv-epidemic
US Public Health Service: Preexposure Prophylaxis for the Prevention of HIV infection in the United States – 2021 Update, A Clinical Practice Guideline. 2021.
US Public Health Service: Preexposure Prophylaxis for the Prevention of HIV infection in the United States – 2017 Update, A Clinical Practice Guideline. 2017.
Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239–54.
pubmed: 32711800
pmcid: 9665936
doi: 10.1016/S0140-6736(20)31065-5
Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.
pubmed: 26624850
doi: 10.1056/NEJMoa1506273
Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA Panel. JAMA. 2018;320(4):379–96.
pubmed: 30043070
pmcid: 6415748
doi: 10.1001/jama.2018.8431
Commissioner O of the. FDA. FDA; 2021. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779–89.
pubmed: 35378077
pmcid: 9077443
doi: 10.1016/S0140-6736(22)00538-4
Landovitz RJ, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L, et al. HPTN083 interim results: Pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM, TGW). In: Journal of the International AIDS Society. JOHN WILEY & SONS LTD THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W …; 2020. p. 183–3.
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595–608.
pubmed: 34379922
pmcid: 8448593
doi: 10.1056/NEJMoa2101016
Spreen W, Min S, Ford SL, Chen S, Lou Y, Bomar M, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14(5):192–203.
pubmed: 24144896
doi: 10.1310/hct1405-192
Smith SJ, Zhao XZ, Burke TR, Hughes SH. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15(1):37.
pubmed: 29769116
pmcid: 5956922
doi: 10.1186/s12977-018-0420-7
Karmon SL, Mohri H, Spreen W, Markowitz M. GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. J AIDS. 2015;68(3):e39-41.
Spreen W, Williams P, Margolis D, Ford SL, Crauwels H, Lou Y, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J AIDS. 2014;67(5):487–92.
Cattaneo D, Gervasoni C. Pharmacokinetics and pharmacodynamics of cabotegravir, a long-acting HIV integrase strand transfer inhibitor. Eur J Drug Metab Pharmacokinet. 2019;44(3):319–27.
pubmed: 30387005
doi: 10.1007/s13318-018-0526-2
Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10(4):239–45.
pubmed: 26049948
pmcid: 5638427
doi: 10.1097/COH.0000000000000168
Bowers GD, Culp A, Reese MJ, Tabolt G, Moss L, Piscitelli S, et al. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147–62.
pubmed: 26134155
doi: 10.3109/00498254.2015.1060372
Ford SL, Sutton K, Lou Y, Zhang Z, Tenorio A, Trezza C, et al. Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects. Antimicrob Agents Chemother. 2017;61(10):10–1128.
doi: 10.1128/AAC.00487-17
Apretude (cabotegravir) [package insert]. Durham, NC: ViiV Healthcare Company; Revised 2/2023.
Andrews CD, Yueh YL, Spreen WR, St. Bernard L, Boente-Carrera M, Rodriguez K, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med. 2015. https://doi.org/10.1126/scitranslmed.3010298 .
doi: 10.1126/scitranslmed.3010298
pubmed: 26631631
pmcid: 4770855
Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151–4.
pubmed: 24594934
pmcid: 4308974
doi: 10.1126/science.1248707
Andrews CD, Bernard LS, Poon AY, Mohri H, Gettie N, Spreen WR, et al. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS. 2017;31(4):461–7.
pubmed: 27902508
doi: 10.1097/QAD.0000000000001343
Dobard C, Makarova N, Nishiura K, Dinh C, Holder A, Sterling M, et al. Long-acting cabotegravir protects macaques against repeated penile simian-human immunodeficiency virus exposures. J Infect Dis. 2020;222(3):391–5.
pubmed: 32128569
doi: 10.1093/infdis/jiaa095
Spreen W, Lowry A, Pal R, Yueh YL, Ford S. Correlation of in vivo cabotegravir concentration & prevention of SIV in macaques. In: Conference on Retroviruses and Opportunistic Infections. 2015. p. 23–6.
Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–40.
pubmed: 28546090
doi: 10.1016/S2352-3018(17)30068-1
Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. Newell ML, editor. PLoS Med. 2018;15(11): e1002690.
pubmed: 30408115
pmcid: 6224042
doi: 10.1371/journal.pmed.1002690
Landovitz RJ, Li S, Eron JJ, Grinsztejn B, Dawood H, Liu AY, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472–81.
pubmed: 32497491
pmcid: 7859863
doi: 10.1016/S2352-3018(20)30106-5
Landovitz RJ, Zangeneh SZ, Chau G, Grinsztejn B, Eron JJ, Dawood H, et al. Cabotegravir is not associated with weight gain in human immunodeficiency virus–uninfected individuals in HPTN 077. Clin Infect Dis. 2020;70(2):319–22.
pubmed: 31125395
doi: 10.1093/cid/ciz439
Transgender women (TGW) in HPTN 083: An evaluation of safety, efficacy, and gender affirming hormonal therapy (GAHT) interactions with long-acting cabotegravir (CAB-LA) - AIDS 2022 – The 24th International AIDS Conference. 2022. https://www.prepwatch.org/wpcontent/uploads/2022/11/AIDS2022_083_TGW_ePoster_Submitted.pdf .
CAB-LA PrEP: Early detection of HIV infection may reduce INSTI resistance risk - CROI Conference. 2022. Available from: https://www.croiconference.org/abstract/cab-la-prep-early-detection-of-hiv-infection-may-reduce-insti-resistance-risk/
Long acting injectable cabotegravir: updated efficacy and safety results from HPTN 084. Available from: https://www.natap.org/2022/IAC/IAC_22.htm
The LEVI Syndrome: Characteristics of early HIV Infection with cabotegravir for PrEP - CROI Conference. 2023. Available from: https://www.croiconference.org/abstract/the-levi-syndrome-characteristics-of-early-hiv-infection-with-cabotegravir-for-prep/
Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L, et al. Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021;224(9):1581–92.
pubmed: 33740057
pmcid: 8599849
doi: 10.1093/infdis/jiab152
Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, et al. Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084. J Infect Dis. 2022;225(10):1741–9.
pubmed: 35301540
pmcid: 9113509
doi: 10.1093/infdis/jiab576
Eshleman SH, Fogel JM, Halvas EK, Piwowar-Manning E, Marzinke MA, Kofron R, et al. HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention. J Infect Dis. 2022;226(12):2170–80.
pubmed: 36240386
pmcid: 10205624
doi: 10.1093/infdis/jiac415
Pilcher CD, Eron JJ, Galvin S, Gay C, Cohen MS. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Investig. 2006;116(12):3292–3292.
pmcid: 1679701
doi: 10.1172/JCI21540C1
Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS. 2008;3(1):10–5.
pubmed: 19372938
doi: 10.1097/COH.0b013e3282f2e295
Breakthrough HIV-1 infection in setting of long-acting cabotegravir for PrEP - CROI Conference. 2023. Available from: https://www.croiconference.org/abstract/breakthrough-hiv-1-infection-in-setting-of-long-acting-cabotegravir-for-prep/
Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis. 2010;202(Supplement_2):S270–7.
pubmed: 20846033
doi: 10.1086/655651
Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;16(8):1119–29.
pubmed: 12004270
doi: 10.1097/00002030-200205240-00005
Greene GJ, Swann G, Fought AJ, Carballo-Diéguez A, Hope TJ, Kiser PF, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS Behav. 2017;21(5):1336–49.
pubmed: 27770215
pmcid: 5380480
doi: 10.1007/s10461-016-1565-9
Parsons JT, Rendina HJ, Whitfield THF, Grov C. Familiarity with and preferences for oral and long-acting injectable HIV Pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the U.S. AIDS Behav. 2016;20(7):1390–9.
pubmed: 27000145
pmcid: 4903901
doi: 10.1007/s10461-016-1370-5
Thigh injections of cabotegravir+rilpivirine in virally suppressed adults with HIV-1 - CROI Conference. 2023. Available from: https://www.croiconference.org/abstract/thigh-injections-of-cabotegravirrilpivirine-in-virally-suppressed-adults-with-hiv-1/
Carnes SK, Sheehan JH, Aiken C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr Opin HIV AIDS. 2018;13(4):359–65.
pubmed: 29782334
pmcid: 6075716
doi: 10.1097/COH.0000000000000472
Yant SR, Mulato A, Stepan G, Villasenor AG, Jin D, Margot NA, et al. GS-6207, a potent and selective first-in-class long-acting HIV-1 capsid inhibitor. In: Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA. 2019. p. 4–7.
Preclinical profile of a novel capsid inhibitor. Seattle, WA; 2019. (Long-Acting/Extended Release Antiretroviral Research Resource Program (LEAP)). Available from: https://longactinghiv.org/sites/default/files/Videos/SC1ATK18JZheng.m4v
Margot N, Ram R, Rhee M, Callebaut C. Absence of lenacapavir (GS-6207) phenotypic resistance in HIV gag cleavage site mutants and in isolates with resistance to existing drug classes. Antimicrob Agents Chemother. 2021;65(3):10–1128.
doi: 10.1128/AAC.02057-20
Sager J, Begley R, Rhee M, West S, Ling J, Escobar J, et al. Safety and PK of subcutaneous GS-6207, a novel HIV-1 capsid inhibitor. In: HIV Medicine. Wiley 111 River ST, Hoboken 07030-5774, NJ USA; 2019. p. 39–39.
Begley R, Rhee M, West S, Worth A, Ling J, German P. PK, food effect, and safety of oral GS-6207, a novel HIV-1 capsid inhibitor. In: Proceedings of the conference on retroviruses and opportunistic infections. 2020.
Begley R, Lutz J, Rhee M, Dvory-Sobol H, Chiu A, West SK, et al. Lenacapavir sustained delivery formulation supports 6-month dosing interval. AIDS. 2020.
Sunlenca (lenacapavir) [package insert]. Foster City, CA: Gilead Sciences, Inc.; Revised 12/2022.
Begley R, Lutz J, Dvory–Sobol H, West S, Kawata K, Ling J, et al. Clinical evaluation of drug interactions with oral lenacapavir and probe drugs. In: HIV MEDICINE. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2021. p. 25–6.
Zeuli JD, Rivera CG, Wright JA, Kasten MJ, Mahmood M, Ragan AK, et al. Pharmacogenomic panel testing provides insight and enhances medication management in people with HIV. AIDS. 2023;37(10):1525–33.
pubmed: 37199600
doi: 10.1097/QAD.0000000000003598
Bekerman E, Vidal S, Hansen D. Long-acting HIV capsid inhibitor effective as PrEP in a SHIV rhesus macaque model. In: Conference on Retroviruses and Opportunisitic Infections Virtual CROI. 2021.
Vidal SJ, Bekerman E, Hansen D, Lu B, Wang K, Mwangi J, et al. Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. Nature. 2022;601(7894):612–6.
pubmed: 34875675
doi: 10.1038/s41586-021-04279-4
Bekerman, E. New PrEP agents and formulations - CROI 2021. Available from: https://www.croiwebcasts.org/console/player/47795?mediaType=slideVideo&
Gilead Sciences. A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16 Years of Age Who Have Sex With Male Partners and Are at Risk for HIV Infection. clinicaltrials.gov; 2023 Jul. Report No.: NCT04925752. Available from: https://clinicaltrials.gov/study/NCT04925752
Gilead Sciences. A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection. clinicaltrials.gov; 2023 Jun. Report No.: NCT04994509. Available from: https://clinicaltrials.gov/study/NCT04994509
Gilead Announces New Arm of HIV Womens Prevention Study. Available from: https://www.gilead.com/news-and-press/company-statements/gilead-announces-new-arm-of-hiv-womens-prevention-study
Duong YT, Kassanjee R, Welte A, Morgan M, De A, Dobbs T, et al. Recalibration of the limiting antigen avidity eia to determine mean duration of recent infection in divergent HIV-1 subtypes. Ceccherini-Silberstein F, editor. PLoS ONE. 2015;10(2): e0114947.
pubmed: 25710171
pmcid: 4339840
doi: 10.1371/journal.pone.0114947
Eichler H, Bloechl-Daum B, Bauer P, Bretz F, Brown J, Hampson L, et al. “Threshold-crossing”: a useful way to establish the counterfactual in clinical trials? Clin Pharmacol Ther. 2016;100(6):699–712.
pubmed: 27650716
pmcid: 5114686
doi: 10.1002/cpt.515
Goring S, Taylor A, Müller K, Li TJJ, Korol EE, Levy AR, et al. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review. BMJ Open. 2019;9(2): e024895.
pubmed: 30819708
pmcid: 6398650
doi: 10.1136/bmjopen-2018-024895
Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, et al. HIV recent infection test-based incidence as a counterfactual for new PREP trials - IAS Conference. 2021. Available from: https://trace-recency.org/wp-content/uploads/2022/05/RAWG_IAS2021_e-poster.pdf
Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med. 2022;386(19):1793–803.
pubmed: 35544387
doi: 10.1056/NEJMoa2115542
VanderVeen L, Margot N, Naik V. Interim resistance analysis of long-acting lenacapavir in treatment-naïve people with HIV at 28 Weeks (CALIBRATE). In: 2021 IDWeek Virtual Conference. 2021.
Shattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med. 2012;2(2):a007385–a007385.
pubmed: 22355798
pmcid: 3281595
doi: 10.1101/cshperspect.a007385
Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, et al. Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett. 2001;11(17):2235–9.
pubmed: 11527705
doi: 10.1016/S0960-894X(01)00412-7
Ludovici DW, Kavash RW, Kukla MJ, Ho CY, Ye H, De Corte BL, et al. Evolution of anti-hiv drug candidatespart 2: diaryltriazine (DATA) analogues. Bioorg Med Chem Lett. 2001;11(17):2229–34.
pubmed: 11527704
doi: 10.1016/S0960-894X(01)00411-5
Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990;250(4986):1411–3.
pubmed: 1701568
doi: 10.1126/science.1701568
Romero DL, Busso M, Tan CK, Reusser F, Palmer JR, Poppe SM, et al. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA. 1991;88(19):8806–10.
pubmed: 1717988
pmcid: 52599
doi: 10.1073/pnas.88.19.8806
Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995;39(12):2602–5.
pubmed: 8592986
pmcid: 162996
doi: 10.1128/AAC.39.12.2602
Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2009;53(2):487–95.
pubmed: 19029331
doi: 10.1128/AAC.01156-08
Van Der Straten A, Montgomery ET, Cheng H, Wegner L, Masenga G, Von Mollendorf C, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African Women. AIDS Behav. 2012;16(7):1775–86.
pubmed: 22644068
doi: 10.1007/s10461-012-0215-0
Devlin B, Nuttall J, Wilder S, Woodsong C, Rosenberg Z. Development of dapivirine vaginal ring for HIV prevention. Antiviral Res. 2013;100:S3-8.
pubmed: 24188702
doi: 10.1016/j.antiviral.2013.09.025
International Partnership For Microbicides. Available from: https://www.ipmglobal.org/
Jespers VA, Van Roey JM, Beets GI, Buvé AM. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J AIDS. 2007;44(2):154–8.
International Partnership for Microbicides, Inc. A Randomized, Double-Blind, Phase 1b Study in Healthy HIV-Negative Women to Evaluate the Pharmacokinetics, Safety, and Bleeding Patterns Associated With 90-Day Use of Core-Sheath Vaginal Rings Releasing Dapivirine and Levonorgestrel. clinicaltrials.gov; 2022. Report No.: NCT05041699. Available from: https://clinicaltrials.gov/study/NCT05041699
Balkus JE, Palanee-Phillips T, Reddy K, Siva S, Harkoo I, Nakabiito C, et al. Brief report: dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. J AIDS. 2017;76(2):e47-51.
Dhondt M, Adriaens E, Roey J, Remon J. The evaluation of the local tolerance of vaginal formulations containing dapivirine using the Slug Mucosal Irritation test and the rabbit vaginal irritation test. Eur J Pharm Biopharm. 2005;60(3):419–25.
pubmed: 15996583
doi: 10.1016/j.ejpb.2005.01.012
Murphy DJ, Desjardins D, Boyd P, Dereuddre-Bosquet N, Stimmer L, Caldwell A, et al. Impact of ring size and drug loading on the pharmacokinetics of a combination dapivirine-darunavir vaginal ring in cynomolgus macaques. Int J Pharm. 2018;550(1–2):300–8.
pubmed: 30153490
doi: 10.1016/j.ijpharm.2018.08.051
Nuttall JP, Thake DC, Lewis MG, Ferkany JW, Romano JW, Mitchnick MA. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14 C]Dapivirine for 7 days. Antimicrob Agents Chemother. 2008;52(3):909–14.
pubmed: 18086845
doi: 10.1128/AAC.00330-07
Holt JDS, Cameron D, Dias N, Holding J, Muntendam A, Oostebring F, et al. The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides. Antimicrob Agents Chemother. 2015;59(7):3761–70.
pubmed: 25845860
pmcid: 4468677
doi: 10.1128/AAC.04954-14
Nel A, Haazen W, Nuttall J, Romano J, Rosenberg Z, Van Niekerk N. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28(10):1479–87.
pubmed: 24901365
doi: 10.1097/QAD.0000000000000280
National Institute of Allergy and Infectious Diseases (NIAID). A Phase 2a crossover trial evaluating the safety of and adherence to a vaginal matrix ring containing dapivirine and oral emtricitabine/tenofovir disoproxil fumarate in an adolescent and young adult female population. clinicaltrials.gov; 2023. Report No.: NCT03593655. Available from: https://clinicaltrials.gov/study/NCT03593655
About the REACH Study (MTN-034) | Microbicide Trials Network. Available from: https://www.mtnstopshiv.org/news/about-reach-study-mtn-034
Nel A, Van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–43.
pubmed: 27959766
doi: 10.1056/NEJMoa1602046
Nel A, Van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A, et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021;8(2):e77-86.
pubmed: 33539761
doi: 10.1016/S2352-3018(20)30300-3
Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32.
pubmed: 26900902
pmcid: 4993693
doi: 10.1056/NEJMoa1506110
Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G, et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV. 2021;8(2):e87-95.
pubmed: 33539762
pmcid: 8038210
doi: 10.1016/S2352-3018(20)30304-0
Liu AY, Dominguez Islas C, Gundacker H, Neradilek B, Hoesley C, Van Der Straten A, et al. Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States. J Int AIDS Soc. 2021. https://doi.org/10.1002/jia2.25747 .
doi: 10.1002/jia2.25747
pubmed: 34822220
pmcid: 8614225
International Partnership for Microbicides, Inc. A Phase 1, randomized pharmacokinetics and safety study of extended duration dapivirine vaginal rings. clinicaltrials.gov; 2019 Jan. Report No.: NCT03234400. Available from: https://clinicaltrials.gov/study/NCT03234400
Parikh UM, Penrose KJ, Heaps AL, Halvas EK, Goetz BJ, Gordon KC, et al. HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial. J Int AIDS Soc. 2021;24(11): e25833.
pubmed: 34762770
pmcid: 8583424
doi: 10.1002/jia2.25833
Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Available from: https://www.who.int/publications-detail-redirect/9789240022232
Karuna ST, Corey L. Broadly neutralizing antibodies for HIV prevention. Annu Rev Med. 2020;71(1):329–46.
pubmed: 31986089
doi: 10.1146/annurev-med-110118-045506
Pancera M, Changela A, Kwong PD. How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Curr Opin HIVAIDS. 2017;12(3):229.
doi: 10.1097/COH.0000000000000360
Lorenzi JC, Mendoza P, Cohen YZ, Nogueira L, Lavine C, Sapiente J, et al. Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates. J Virol. 2021;95(5):e01909-e1920.
pubmed: 33298542
pmcid: 8092834
doi: 10.1128/JVI.01909-20
Pegu A, Yang Z, Boyington JC, Wu L, Ko SY, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Trans Med. 2014;6(243):243ra88.
doi: 10.1126/scitranslmed.3008992
Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nature Med. 2014;20(3):296–300.
pubmed: 24509526
doi: 10.1038/nm.3471
Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O’Brien C, et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10–1074 in healthy adults: a randomized, phase 1 study. PLoS ONE. 2019;14(8): e0219142.
pubmed: 31393868
pmcid: 6687118
doi: 10.1371/journal.pone.0219142
Gaudinski MR, Houser KV, Doria-Rose NA, Chen GL, Rothwell RSS, Berkowitz N, et al. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV. 2019;6(10):e667–79.
pubmed: 31473167
doi: 10.1016/S2352-3018(19)30181-X
Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nature Med. 2022;28(6):1288–96.
pubmed: 35551291
doi: 10.1038/s41591-022-01815-1
Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021;384(11):1003–14.
pubmed: 33730454
pmcid: 8189692
doi: 10.1056/NEJMoa2031738
Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med. 2016;375(21):2037–50.
pubmed: 27959728
pmcid: 5292134
doi: 10.1056/NEJMoa1608243
Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, et al. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial. PLoS Med. 2017;14(11): e1002435.
pubmed: 29136037
pmcid: 5685476
doi: 10.1371/journal.pmed.1002435
Edupuganti S, Mgodi N, Karuna ST, Andrew P, Rudnicki E, Kochar N, et al. Feasibility and successful enrollment in a proof-of-concept HIV prevention trial of VRC01, a broadly neutralizing HIV-1 monoclonal antibody. J AIDS (1999). 2021;87(1):671.
Ledgerwood JE, Coates EE, Yamshchikov G, et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015;182(3):289–301.
pubmed: 26332605
pmcid: 4636891
doi: 10.1111/cei.12692
Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18:465–71.
pubmed: 10855789
doi: 10.1023/A:1006341717398
Takuva S, Karuna ST, Juraska M, Rudnicki E, Edupuganti S, Anderson M, et al. Infusion reactions after receiving the broadly neutralizing antibody VRC01 or placebo to reduce HIV-1 acquisition: results from the phase 2b antibody-mediated prevention randomized trials. J AIDS. 2022;89(4):405–13.
Landovitz RJ, Donnell D, Tran H. Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs TDF/FTC for PrEP. CROI; 2022 Feb 12-16; Virtual.